1. Home
  2. TOVX vs MTNB Comparison

TOVX vs MTNB Comparison

Compare TOVX & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TOVX
  • MTNB
  • Stock Information
  • Founded
  • TOVX 2001
  • MTNB 2013
  • Country
  • TOVX United States
  • MTNB United States
  • Employees
  • TOVX N/A
  • MTNB N/A
  • Industry
  • TOVX Biotechnology: Pharmaceutical Preparations
  • MTNB Biotechnology: Pharmaceutical Preparations
  • Sector
  • TOVX Health Care
  • MTNB Health Care
  • Exchange
  • TOVX Nasdaq
  • MTNB Nasdaq
  • Market Cap
  • TOVX 4.5M
  • MTNB 5.2M
  • IPO Year
  • TOVX 2006
  • MTNB N/A
  • Fundamental
  • Price
  • TOVX $0.43
  • MTNB $0.87
  • Analyst Decision
  • TOVX Hold
  • MTNB Hold
  • Analyst Count
  • TOVX 1
  • MTNB 1
  • Target Price
  • TOVX N/A
  • MTNB N/A
  • AVG Volume (30 Days)
  • TOVX 371.0K
  • MTNB 46.9K
  • Earning Date
  • TOVX 08-12-2025
  • MTNB 08-13-2025
  • Dividend Yield
  • TOVX N/A
  • MTNB N/A
  • EPS Growth
  • TOVX N/A
  • MTNB N/A
  • EPS
  • TOVX N/A
  • MTNB N/A
  • Revenue
  • TOVX N/A
  • MTNB N/A
  • Revenue This Year
  • TOVX N/A
  • MTNB N/A
  • Revenue Next Year
  • TOVX N/A
  • MTNB N/A
  • P/E Ratio
  • TOVX N/A
  • MTNB N/A
  • Revenue Growth
  • TOVX N/A
  • MTNB N/A
  • 52 Week Low
  • TOVX $0.40
  • MTNB $0.47
  • 52 Week High
  • TOVX $7.15
  • MTNB $8.50
  • Technical
  • Relative Strength Index (RSI)
  • TOVX 39.54
  • MTNB 42.07
  • Support Level
  • TOVX $0.45
  • MTNB $0.82
  • Resistance Level
  • TOVX $0.49
  • MTNB $1.04
  • Average True Range (ATR)
  • TOVX 0.04
  • MTNB 0.05
  • MACD
  • TOVX -0.00
  • MTNB -0.02
  • Stochastic Oscillator
  • TOVX 17.79
  • MTNB 23.77

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

About MTNB Matinas Biopharma Holdings Inc.

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

Share on Social Networks: